Long-term Efficacy and Safety of the Implantable Collamer Lens in Eyes With an Anterior Chamber Depth of 2.6 to 2.8 mm

Evidence database / Studies / kong-2026-icl-shallow-anterior-chamber-long-term

41enrolled patients*

41enrolled eyes*

1structured arms

—maximum standardized days follow-up

* Descriptive sum of reported arm counts. “≥” indicates that one or more arm counts were not reported; missing values are not treated as zero.

Study arm

ICL V4c in shallow anterior chambers

ICLEVO Implantable Collamer Lens

Population

Patients: 41
Eyes: 41
Bilateral treatment: Not reported
Age range: 21 to 42 years
Sphere range: -21 to -3.5 D
Cylinder range: -3.75 to 0 D
Spherical equivalent: Not reported
Corneal thickness: Not reported

Eligibility definition

Inclusion
Myopia or myopic astigmatism; anterior chamber depth 2.6–2.8 mm; ICL V4c implantation.

Exclusion
Not structured

Reported outcomes by follow-up

Outcome	Follow-up	Follow-up sample	Result	Reported fraction	Provenance
Mean uncorrected distance acuity efficacy	Final visit: 6–10 years (mean 7.76 years)	41 eyes	0.150 logMAR	denominator: 41 eyes	VERIFIED Source · Table 1
Loss of corrected distance acuity (any lines) safety	Final visit: 6–10 years (mean 7.76 years)	41 eyes	0%	denominator: 41 eyes	VERIFIED Source · Abstract
Mean endothelial cell density decrease safety	Final visit: 6–10 years (mean 7.76 years)	41 eyes	9.4%	denominator: 41 eyes	VERIFIED Source · Abstract

Complications

Complication	Follow-up	Reported rate	Reported fraction	Provenance
Peripheral anterior subcapsular cataract	Final visit: 6–10 years (mean 7.76 years)	7.3%	3 / 41	Source · Abstract

Study design

Retrospective noncomparative case series of one eye per patient with anterior chamber depth 2.6–2.8 mm.

Country: China
Publication-reported places: Eye and ENT Hospital, Fudan University, Shanghai, China
Multicenter: No
Prospective: No
Randomized: No
Source type: RETROSPECTIVE
Regulator: Not reported

Place metadata may refer to a treatment site, institution or author affiliation. Confirm its role in the linked publication.

Limitations and notes

Selected shallow-anterior-chamber cohort; not representative of all ICL recipients. Final visits span 6–10 years (mean 7.76 years), so no single standardized day is assigned. Table 1 supplies baseline ranges. Endothelial loss was reported; monitoring remains necessary.

Missing fields are not interpreted as negative findings. Arm counts may not be additive in all study designs.

Study evidence level
A simple, non-GRADE hierarchy based on design: randomized and large regulatory trials are high; prospective cohorts moderate; retrospective observational studies low. Manual review can override this label.